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Background: Homeostatic B Cell-Attracting chemokine 1 (BCA-1) otherwise known as CXCL13 is constitutively
expressed in secondary lymphoid organs by follicular dendritic cells (FDC) and macrophages. It is the only known
ligand for the CXCR5 receptor, which is expressed on mature B cells, follicular helper T cells (Tfh), Th17 cells and
regulatory T (Treg) cells. Aberrant expression of CXCL13 within ectopic germinal centers has been linked to the
development of autoimmune disorders (e.g. Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosis).
We, therefore, hypothesized that antibody-mediated disruption of the CXCL13 signaling pathway would interfere
with the formation of ectopic lymphoid follicles in the target organs and inhibit autoimmune disease progression.
This work describes pre-clinical development of human anti-CXCL13 antibody MAb 5261 and includes therapeutic
efficacy data of its mouse counterpart in murine models of autoimmunity.
Results: We developed a human IgG1 monoclonal antibody, MAb 5261 that specifically binds to human, rodent
and primate CXCL13 with an affinity of approximately 5 nM and is capable of neutralizing the activity of CXCL13
from these various species in in vitro functional assays. For in vivo studies we have engineered a chimeric antibody
to contain the same human heavy and light chain variable genes along with mouse constant regions. Treatment with this
antibody led to a reduction in the number of germinal centers in mice immunized with 4-Hydroxy-3-nitrophenylacetyl
hapten conjugated to Keyhole Limpet Hemocyanin (NP-KLH) and, in adoptive transfer studies, interfered with the
trafficking of B cells to the B cell areas of mouse spleen. Furthermore, this mouse anti-CXCL13 antibody demonstrated
efficacy in a mouse model of Rheumatoid arthritis (Collagen-Induced Arthritis (CIA)) and Th17-mediated murine model
of Multiple Sclerosis (passively-induced Experimental Autoimmune Encephalomyelitis (EAE)).
Conclusions: We developed a novel therapeutic antibody targeting CXCL13-mediated signaling pathway for the
treatment of autoimmune disorders.
Keywords: CXCL13, Chemokine, Monoclonal antibody, Collagen-induced arthritis, Experimental autoimmune
encephalomyelitisBackground
Chemokines are small (7–15 kDa) inducible peptides in-
volved in migration and retention of leukocytes in tis-
sues under physiological and pathological conditions.
The chemokines exert their effects through G-protein
coupled receptors on target cells. Despite the potential
pitfalls (promiscuity in chemokine/receptor interactions;
multiple chemokine targets in any given pathologic
conditions; broad receptor distribution), the chemokine
system represents an attractive therapeutic target for a* Correspondence: mzauderer@vaccinex.com
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ogy disorders and all components of the system can be
potentially targeted by therapeutic agents.
The chemokine CXCL13 is constitutively expressed in
secondary lymphoid organs (spleen, lymph nodes and
Peyer’s patches) by FDC and macrophages [1,2]. CXCL13
primarily acts through G-protein-coupled CXCR5 recep-
tor (Burkitt’s lymphoma receptor 1) expressed on mature
B lymphocytes [3,4], CD4+ follicular helper T cells, (Tfh,
antigen-primed Th cells [5,6], CD4+ Th17 cells [7], minor
subset of CD8+ T cells and activated tonsil Treg cells
[8,9]. CXCL13 has also been shown to interact along with
the inflammatory chemokines CXCL9, CXCL10 andntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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than with CXCR5. Expression of CXCR3 is highly re-
stricted to activated T and NK cells [10].
In the absence of infection and during normal immune
responses, CXCL13 and its receptor CXCR5 are involved
in the homing of B-cells and follicular B-helper T cells
into primary follicles in lymph nodes and spleen [11],
and in germinal center formation and lymphoid organo-
genesis. Thus, CXCL13 and CXCR5-deficient mice ex-
hibit impaired development of Peyer’s patches and
lymph nodes due to the lack of organized follicles.
Moreover, immunization with T-cell-dependent antigen
in the context of CXCL13 knockout phenotype led to
the formation of misplaced and abnormally small germi-
nal centers in lymph nodes and spleens [12].
Generation of B cells with potential for autoantibody
production is a common occurrence under normal
physiological conditions. Such natural autoantibodies
are, however, low affinity IgM antibodies that exhibit
wide-spectrum reactivity and strong preference for sol-
uble self antigens over those expressed on cell surface
[13,14]. Autoreactive low-affinity B cells undergo apop-
tosis and, therefore, are unlikely to present any danger
to a healthy organism.
In a chronically-inflamed environment, ectopic germi-
nal centers form within affected (often non-lymphoid)
tissues. CXCL13 over-expression by FDC in these germi-
nal centers is accompanied by dysregulation of interac-
tions among FDCs, B cells and follicular Th cells [15]
and reduced elimination of autoreactive B cells. Subse-
quent, antigen-driven generation of affinity-matured long-
lived plasma cells and memory B cells producing high
affinity IgG autoantibodies contributes to the development
of autoimmune and inflammatory disorders.
Th17 cells, a subset of the Th family, produce cytokines
IL17, IL21 and IL22 and, under normal circumstances,
play an important role in host defense against extracellular
pathogens (e.g., bacteria, fungi). Under pathological condi-
tions, however, Th17 cells have been linked to the devel-
opment of autoimmune inflammation, allergic disorders
and cancer [16-18]. In the context of CXCL13 biology,
Th17 cells are of particular interest as both human and
mouse Th17 cells express CXCR5 receptors and are able
to migrate towards CXCL13 in vitro [8]. Human allo-
reactive and pathogen-specific Th17, but not Th1 or Th2,
clones were shown to express CXCL13, which may con-
tribute to optimal Th17-B cell interactions necessary for
antibody production [19,20]. Moreover, statistically signifi-
cant correlation between IL-17 and CXCL13 levels in syn-
ovial fluid of patients with rheumatoid arthritis has been
observed. Dramatic increases in myelin-specific Th17 cells
in peripheral blood of patients with relapsing-remitting
MS correlated with disease activity [21]. In patients with
progressive MS, Th17 cells in cooperation with Tfh andactivated B cell subsets have been shown to play a critical
role in systemic inflammation associated with the develop-
ment of meningeal ectopic lymphoid follicle-like struc-
tures (ELFs) and progression of the disease [22].
The family of autoimmune and inflammatory disorders
where CXCL13 appears to be involved in disease patho-
genesis and constitutes an attractive therapeutic target
includes, among others, Multiple Sclerosis (MS) [23-26],
Rheumatoid Arthritis (RA) [27-30]; Hashimoto’s thyroid-
itis [31], chronic gastritis/MALT lymphoma [32,33], graft
rejection syndrome [34], Sjogren’s Syndrome [35]; Sys-
temic Lupus Erythematosis [36], and Myastenia Gravis
[37]. The mechanism of action for CXCL13-targeting
treatments would involve blockade of CXCL13 inter-
action with its receptor resulting in inhibition of B, Tfh
and Th17 cell migration and subsequent interference
with the formation of ectopic germinal centers and de-
velopment of tissue inflammation. Described below is
the derivation and testing of a novel monoclonal anti-
CXCL13 antibody that binds human, cynomolgus mon-
key and mouse CXCL13. We demonstrate that this
monoclonal antibody is able to inhibit in vitro functional
activity of human and mouse CXCL13 and present effi-
cacy data of its murine analog in murine models of
autoimmunity.
Results
Generation of human anti-CXCL13 antibody
Human anti-CXCL13 antibody, MAb 5261, was gener-
ated as described in detail in Methods section and illus-
trated in Figure 1. First, mouse hybridoma was produced
by fusing myeloma cells with splenocytes from a mouse
immunized with human CXCL13. Mouse monoclonal
antibody, selected based on its ability to bind both hu-
man and mouse CXCL13, was then used as a source of
V genes for the generation of the mouse-human anti-
body chimera. Humanization of the chimeric antibody
and selection of higher affinity variants using Vaccinex’s
proprietary ActivMAb® technology, led to the creation of
anti-human CXCL13 antibody MAb 5261. For the
in vivo experiments, we generated a MAb 5261-based
chimeric antibody containing the human V genes and
mouse constant domains (Figure 1).
To confirm CXCL13 specificity of MAb 5261 and
MAb 5261-muIg we employed the following assays (data
not shown): ELISA on a panel of recombinant human,
murine and cynomolgus monkey CXCL13, human CXC
chemokines most homologous to CXCL13 (CXCL12,
CXCL8, CXCL10, and CXCL9; [38]) and various non-
specific antigens (e.g., streptavidin, bovine serum albu-
min, human serum albumin, insulin, hemoglobin); flow
cytometry on a panel of cell lines; and IHC on a panel of
31 normal human tissues. We found both antibodies to be
specific for recombinant human, murine and cynomolgus
Swiss Webster mice 
immunized
with KLH – conjugated 
human CXCL13
Human MAb 5261 MAb 5261-muIg
V gene cloning; chimeric Mab generation; conversion to fully human antibody 
and selection of higher affinity variants using Vaccinex ActivMAb technology.
Antibody screening in specificity and functional assays
Hybridoma generation; selection 
of clone (3D2) that neutralizes both,
human and mouse CXCL13
Murine CXCL13 
antibody (3D2)
Generation of murine counterpart for
in vivo studies: same heavy and light
chain V regions as Mab 5261; murine
IgG2a and kappa constant regions
Figure 1 Generation of MAb 5261 and its murine counterpart.
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these species was determined by Biacore to be 5 nM for
both human and chimeric antibodies. In addition, MAb
5261 efficiently bound CXCL13 from native sources (data
not shown): human (from supernatants collected from
IFN-γ-stimulated human monocytic cell line THP-1) and
mouse (from CXCL13-rich organ extracts from TNF-α
transgenic mice).
Inhibition of CXCL13-mediated chemotaxis
The ability of MAb 5261 and MAb 5261-muIg to inhibit
human CXCL13-induced cell migration was confirmed
using stable cell line human pre-B-697-hCXCR5 and pri-
mary human tonsil cells (Figure 2A and B, respectively).
The effect on mouse CXCL13-mediated chemotaxis was
demonstrated using splenocytes from C57BL/6 and SJL/J
mice (Figure 2C and D, respectively), where we observed
a concentration-dependent inhibition of splenocyte migra-
tion towards CXCL13 by each MAb. Migration of human
pre-B-697-hCXCR4 cells or mouse splenocytes towards
human or murine CXCL12 respectively, was used to con-
firm specificity of each anti-CXCL13 MAb (Figure 2E). In
summary, both MAb 5261 and MAb 5261-muIg met
functional acceptance criteria that included inhibition ofCXCL13-induced migration without affecting CXCL12-
induced migration.Inhibition of human CXCL13-mediated endocytosis of
human CXCR5 receptor
Characteristically of all chemokine receptors, binding of
a chemokine leads to an internalization of the ligand-
receptor complex with subsequent activation of the as-
sociated intracellular signaling cascade [39]. Burkle
and colleagues [40] demonstrated that incubation of
human CXCL13 with chronic lymphocytic leukemia
(CLL) cells expressing high levels of functional CXCR5
receptor led to time- and dose-dependent receptor
endocytosis. We adapted a flow cytometry-based method
described in Burkle et al. to evaluate the ability of MAb
5261 and MAb 5261-muIg to inhibit CXCL13-mediated
CXCR5 receptor internalization in human cells.
Figure 3 shows the effects of MAb 5261 and MAb
5261-muIg on human CXCR5 receptor expression on
the surface of human pre-B-697-hCXCR5 cells treated
with human CXCL13. Both antibodies efficiently and in
a titratable manner interfered with CXCL13-induced in-




Figure 2 (See legend on next page.)
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Figure 2 Effect on CXCL13- (A-D) and CXCL12- (negative control; E) induced migration of human and murine cells. Human pre-B-697-
hCXCR5 cells (A, E), human pre-B-697-hCXCR4 cells (E), human tonsillar cells (B, E), C57BL/6 splenocytes (C, E), and SJL mouse splenocytes (D, E)
were seeded into Transwell inserts. Diluted chemokines +/− antibodies were added into the lower chambers and plates were incubated for 2 h
at 37°C (50 ug/ml of each antibody were used in CXCL12-induced migration assay). Inserts were removed and Alamar blue was added to the
wells and incubated at 37°C overnight. Fluorescence was measured at wavelengths of 530 nm and 590 nm and the percent inhibition of
chemokine-induced migration (A-D) or migration index (E) was calculated. Data represents an average of the measurements from at least three
independent experiments + SEM. Statistical significance (relative to the isotype controls) was evaluated using one-way ANOVA followed by
Bonferroni’s multiple comparison post test **** P < 0.0001; *** P < 0.0003; **P < 0.01.
Klimatcheva et al. BMC Immunology  (2015) 16:6 Page 5 of 17Murine anti-CXCL13 antibody affects splenic homing of
adoptively transferred B cells in naïve BALB/c mice
An in vivo functional assay was subsequently performed
to determine if MAb 5261-muIg would inhibit the pri-
mary function of CXCL13, namely the homing of B cellsA
B
Figure 3 Inhibition of human CXCL13-mediated internalization of hum
pre-blocked with anti-human Fc for 15 min at 37°C, incubated with a pre-c
stained with anti-human CXCR5 antibody for flow cytometric analysis.
values were determined by FlowJo 7.6 software. (B) EC50 values were
graph) with R2 values equal to 0.9 (MAb 5261) and 0.98 (MAb 5261-m
from 3 independent experiments.to the follicles in secondary lymphoid organs. To this
end, an adoptive transfer experiment was conducted in
female BALB/c mice where B cells were isolated from
spleens of untreated donor mice, labelled with CFSE,
and injected intravenously into recipient mice that werean CXCR5 receptor. Human pre-B-697-huCXCR5 cells were
omplexed huCXCL13/antibody mix for 2 h at 37°C, and subsequently
(A) Cell surface CXCR5 receptor expression. Geometric mean
calculated from sigmoidal dose response curves (shown on the
uIg). Data points represent an average of measurements obtained
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either MAb 5261-muIg or control antibody for 2 weeks
prior to adoptive transfer. Twenty four hours post-
transfer, spleens were collected from the recipient mice
and analyzed by flow cytometry and IHC to detect the
presence of labeled B cells. As shown in Figure 4, migra-
tion of CFSE-labeled donor B cells into recipient spleens
showed a trend to being reduced in MAb 5261-muIg-
treated animals, indicating that this anti-CXCL13 spe-
cific antibody impedes B cell homing to a secondary
lymphoid organ.
Effect of murine anti-CXCL13 antibody on isotype class
switching, frequency of high affinity NP-specific IgG1
producing cells and on the size and number of germinal
centers in spleens of mice immunized with
alum-precipitated NP-KLH
Arnold et al. reported an impaired germinal center re-
sponse in mice with CXCR5-deficient T cells that mani-
fested in a reduction in size and number of germinal
centers with a reduction in the frequency of germinalControl Ab
B
A
Figure 4 MAb 5261-muIg-mediated inhibition of B cell migration into
with 30 mg/kg of an Isotype Control Ab or MAb 5261-muIg intraperitonea
donor B cells (2x107 cells per mouse; i.v.). (A) Percentage of CFSE+ B cells i
data were analyzed using FlowJo 7.6 software. Statistical significance was e
spleen sections where CFSE-labeled adoptively transferred cells are green acenter B cells and parallel reduction in frequency of NP-
specific IgG1-secreting cells in spleens and bone marrow
[41]. To determine if antibody-mediated inhibition of
CXCL13 function would have a similar effect on forma-
tion of germinal centers in secondary lymphoid organs
and isotype class switching by naïve B cells, we treated
C57BL/6 mice immunized with alum-precipitated thymus-
dependent antigen, 4-Hydroxy-3-nitrophenylacetyl conju-
gated keyhole limpet hemocyanin (NP-KLH) with MAb
5261-muIg or an appropriate isotype control antibody.
Similar to the results described by Arnold and col-
leagues, on day 12 post-immunization, no difference in
the frequency of splenic NP-specific IgM-secreting cells
was observed between control and MAb 5261-muIg
treated groups (Figure 5A). However, the mean fre-
quency of class-switched NP-specific IgG1-secreting
cells (both total (Figure 5A) and high-affinity (Figure 5B)
antibody) was reduced in the animals treated with MAb
5261-muIg. The proportion of high affinity antibodies in
the total IgG1 population (approximately 70% in each
treatment group) was not affected, indicating a defect inMab 5261-muIg
B220
CFSE
the spleens of naïve BALB/c mice. Recipient mice were treated
lly twice a week for 2 weeks before adoptive transfer of CFSE-labeled
n mouse spleens (n = 3/group) as measured by flow cytometry. Flow
valuated using unpaired Student’s t-test (B) IHC on representative




Figure 5 Effect of murine anti-CXCL13 antibody on germinal center formation in C57BL/6 mice challenged with NP-KLH. Mice were
treated with 30 mg/kg of MAb 5261-muIg antibody and corresponding mouse isotype control, on days −3, 0 (the day of the immunization), 4
and 7 (n = 9/group). (A) Total IgM and IgG1 anti-NP antibody-secreting cells were detected by ELISPOT on wells coated with NP14-BSA. (B) The
frequencies of high affinity IgG1 anti-NP-secreting cells were determined by ELISPOT on wells coated with NP4-BSA. (C) Number of germinal
centers (n = 9 mice/group). Follicles were hand counted. Number of PNA+ germinal centers in relation to total number of follicles per group was
calculated using ImagePro software. (D) Mean germinal center area. Area of each PNA+ germinal center for each group was calculated using
ImagePro software by PNA+ pixel area and then converted to μm. The numbers of GC analyzed were: 201 in Control group and 102 in MAb
5261-muIg-treated group. (E) Percentages of activated T cells (CD4+/CD62Llow/CD44+) in spleens and bone marrow. Statistical significance was
evaluated by Student’s unpaired t-test. *P = 0.0125; **P = 0.0016; ****P < 0.0001; P = 0.2 and 0.71 for IgG1 and IgM portions of the graph,
respectively (A).
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tion in the number of antibody-producing B cells in the
germinal centers of treated animals. We also observed a
significant reduction in number and size of the germinal
centers in the spleens of animals treated with MAb5261-muIg compared with the control group (Figure 5C
and D, respectively), and a reduction in numbers of acti-
vated CD4 + T cells in spleens and bone marrow of MAb
5261-muIg antibody-treated animals (Figure 5E). These
data suggest that the potential mechanism of action of
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mediated recruitment of B and CXCR5+ CD4+ T cells
into lymphoid follicles with subsequent interference with
the formation and expansion of germinal centers.
Murine anti-CXCL13 antibody reduces the severity of
Collagen-Induced Arthritis
Collagen-induced arthritis in mice and rats is a well-
established model of human rheumatoid arthritis [42].
The disease is typically induced by intradermal injection
of bovine type II collagen emulsified in Complete
Freund’s Adjuvant (CFA) and is characterized by the
production of mouse collagen antibodies and subsequent
progressive development of arthritis in the paws. The
role of CXCL13 in CIA pathogenesis has been previously
highlighted. For example, Zheng et al. demonstrated that
treatment with polyclonal anti-CXCL13 antibodies re-
duced disease severity and inhibited formation of germi-
nal centers in the joints of mice affected by CIA [43].
Similarly Finch and colleagues reported that in mice
with an established CIA, CXCL13 neutralization with rat
anti-murine CXCL13 antibodies led to B cell depletion
in the lymphoid tissues and significantly reduced severity
of joint destruction [44].
To assess the therapeutic potential of MAb 5261-muIg
in CIA, arthritis was induced in male DBA/1 J mice. The
mice were subjected to either prophylactic or thera-
peutic treatment regimens that consisted of bi-weekly
injections of 30 mg/kg of antibody. Anti-CXCL13 anti-
bodies were delivered intraperitoneally, while positive
control antibody, Etanercept (Enbrel®, Amgen), was de-
livered subcutaneously. Prophylactic treatment began on
day 20 post-collagen immunization, 1 day prior to the
booster immunization and continued for 3 weeks.
Therapeutic treatment was initiated when the group
mean arthritic index (AI) reached 3–4 (approximately
on day 30 post-initial immunization) and continued for
2 weeks.
As evident from Figure 6A-C, prophylactic treatment
with MAb 5261-muIg resulted in a delay in disease on-
set and reduced rate of disease development. Thera-
peutic treatment with MAb 5261-muIg (Figure 6D-F),
although initiated after onset of arthritis, resulted in a
significantly curtailed disease development, similar to
positive control Etanercept. In both study designs, joints
of the control mice exhibited severe inflammation, mod-
erate cartilage damage with minimal pannus formation
and bone resorption in the ankle and all digit joints
(Figure 6C and F). Minimal inflammation and cartilage
damage were observed in the mice prophylactically
treated with MAb 5261-muIg (Figure 6C). In the thera-
peutic cohort, no lesions were observed in hind paws
and ankles of animals treated with either MAb 5261-
muIg or Etanercept (Figure 6F). Despite the effect ondisease development and progression, serum anti-collagen
II antibody titers were not affected by the treatment with
MAb 5261-muIg (data not shown).
Murine anti-CXCL13 antibody attenuates symptoms in
experimental autoimmune encephalomyelitis
Experimental Autoimmune Encephalomyelitis, an ani-
mal model of multiple sclerosis, is a demyelinating dis-
ease of the CNS that progressively results in escalating
degrees of ascending paralysis with inflammation pri-
marily targeting the spinal cord. EAE can assume an
acute, chronic or relapsing-remitting course and can be
induced in mice either actively by immunization with
myelin antigens (e.g., myelin oligodendrocyte glycopro-
tein (MOG); proteolipid protein (PLP)) or passively via
adoptive transfer of myelin-specific CD4+ T cells from
actively immunized donors to naïve recipients [45,46].
Exploring the role of CXCL13 in EAE pathogenesis,
Bagaeva et al. demonstrated that follicles containing B-
cells and CXCL13-expressing dendritic cells formed in
inflamed meninges of mice with relapsing-remitting
EAE with levels of CXCL13 expression rising steadily
throughout the course of disease [47]. Moreover,
CXCL13-deficient mice experienced mild disease with
decreased relapse rate, while blockade of CXCL13 with
anti-CXCL13 MAb led to disease attenuation in pas-
sively induced EAE in B10.PL mice.
We initially tested mouse antibody 3D2, the prototype
of MAb 5261 (Figure 1), in SJL/J relapsing-remitting
model of EAE where this MAb attenuated disease pro-
gression in 3 independent experiments (data not shown).
Encouraged by the results, we used the same model of
EAE to evaluate the effects of MAb 5261-muIg. The
treatment started on day 7 post-immunization and con-
sisted of weekly intraperitoneal injections with 30 mg/kg
of the antibodies. As evident from data shown in Figure 7,
the treatment with MAb 5261-muIg resulted in significant
reduction in the severity of relapsing-remitting EAE.
To separate EAE-inducing T cell subsets and, thereby,
gain better understanding of the mechanism of action of
MAb 5261-muIg in EAE models, we employed a passive
method of EAE induction. For that, we chose two CD4+
cell subsets: IL-17-secreting Th17 cells and IFN-γ-secreting
Th1 cells. As previously reported by Jager et al., in adop-
tive transfer model of EAE both cell types produced typ-
ical demyelinating lesions in white matter, with twice as
many lesions present in Th17-induced animals [48]. Th1
cell recipients developed classic paralytic symptoms of
EAE, while the recipients of Th17 cells in addition to the
classical symptoms, also developed atypical signs of the
disease that included ataxia, severe imbalance, weight loss
and high mortality rate [49,50]. Peters and colleagues
demonstrated that in a mouse model of passive EAE,
adoptively transferred CXCR5+ Th17 cells, but not other
F5261-muIg: Hind Paw
Etanercept: Ankle Etanercept: Hind Paw
5261-muIg: Ankle
Control Ab: Ankle Control Ab : Hind Paw
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Figure 6 (See legend on next page.)
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Figure 6 Effect of prophylactic and therapeutic treatment with MAb 5261-muIg on CIA progression. (A-C) Prophylactic treatment. (D-F)
Therapeutic treatment. (A and D) Arthritic indexes (AI). (B and E) Summary of the histological analysis. Statistical significance was evaluated using
unpaired Student’s t-test (n = 10 mice/group); **P < 0.001; ****P < 0.0001. (C and F) Toluidine blue staining of the selected limbs. (C): AI at termination:
11 (control), 4 (MAb 5261-muIg). (F): AI at termination: 10 (control), 6 (MAb 5261-muIg), 4 (Etanercept). B – Bone, C – Cartilage, Syn – Synovial tissue.
Thick arrows identify affected joints; yellow arrow – pannus; red arrow – infiltration of inflammatory cells. Results shown are representative of at least
three independent experiments.
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of ectopic lymphoid follicle-like structures (ELFs) in the
CNS through the upregulation of CXCL13 expression and
action of Th17-specific cytokine IL-17 [51]. Based on the
latter observation, we hypothesized that MAb 5261-muIg
would predominantly affect Th17-mediated disease.
Passive EAE was induced in female SJL/J mice by
adoptive transfer of Th1 or Th17 enriched cells differen-
tiated from T cells of donors actively immunized with
PLP139–151. Starting on the day of the adoptive transfer,
the animals were treated with 30 mg/kg of the anti-
bodies, intraperitoneally, twice a week for a total of
4 weeks. The mice were scored for the clinical signs of
the disease as described in Methods. MAb 5261-muIg
significantly reduced the severity of Th17-induced EAE
(Figure 8A and B), but failed to alleviate the symptoms
of Th1-induced EAE (Figure 8B), indicating a specific
mechanism of disease inhibition that involves Th17-
mediated pathways. To further confirm the effect of
MAb 5261-muIg on Th17 cells, we tested this MAb in a
Th17-targeted chemotaxis assay where the antibody
inhibited CXCL13-mediated migration of Th17 cells,
without affecting migration of Th1 cells (Figure 8C).
Tolerability of MAb 5261-muIg and MAb 5261 treatment
In both models, CIA and EAE, we found MAb 5261-muIg
to be well tolerated, as no anti-drug antibody response
(ADA) was detected by ELISA. Treatment regimen of bi-
weekly intraperitoneal injections with 0.6 mg/ml MAb
5261-muIg typically resulted in steady serum levels of ap-
proximately 500 μg/ml of the antibody at study termin-
ation (usually at 2 weeks following the last antibody
injection).
To evaluate the safety of our human anti-CXCL13
antibody, MAb 5261, we conducted a single-dose toxi-
cology study at Ethox International, STS Life Sciences.
Sprague Dawley rats were injected intravenously with
MAb 5261 in doses ranging from 0.01 to 100 mg/kg.
The antibody half-life was dose-dependent with values
ranged from 1 to 14 days. No toxicity or immunogen-
icity was observed in any of the treatment groups.
Discussion
CXCL13 is a homeostatic chemokine that is constitutively
expressed in secondary lymphoid tissue and involved inlymphoid organogenesis. In the setting of disease, how-
ever, the levels of CXCL13 have been shown to signifi-
cantly increase. In fact, in a number of the autoimmune
disorders (e.g., MS [52], SLE [53], Sjogren’s syndrome [38]
and RA [27,54]), CXCL13 is considered a biomarker indi-
cative of disease severity.
Antibody-based therapeutics targeting chemokine–
mediated pathways are promising due to the specificity
of their effect and the ability to enhance immune re-
sponses through activation of complement-dependent
or antibody-dependent cytotoxicity (CDC and ADCC,
respectively) that might be useful in certain disease
states. In recent years, several anti-chemokine antibody
therapeutics have emerged and been tested in clinical
trials [55]. One of them, fully human anti-CXCL10 anti-
body MDX-1100 (aka BMS-936557; Bristol Myers Squibb)
has demonstrated efficacy in Phase II clinical trials involv-
ing patients with rheumatoid arthritis [56] and ulcerative
colitis [57].
We describe here a novel human anti-human CXCL13
antibody, MAb 5261, whose murine analog, MAb 5261-
muIg, has demonstrated efficacy in two well-characterized
mouse models of autoimmunity: CIA (both prophylactic
and therapeutic models) and passively and actively in-
duced models of relapsing-remitting EAE.
In the model of an established arthritis, the effect of
antibody 5261 was comparable to that of Etanercept, a
drug routinely prescribed to treat moderate to severe
RA. Etanercept is a soluble TNF-α receptor fusion protein.
Although effective in RA, Etanercept, as other TNF-α
blockers, is an immunosuppressant and is associated
with a number of serious side effects (unusual cancers,
infections, congestive heart failure, CNS problems, and
autoimmunity) [58], thus suggesting a need for safer
treatment options, one of which might be an antibody
targeting CXCL13.
In the EAE model, MAb 5261-muIg reduced severity
of the disease mediated by CXCR5+ Th17 cells presum-
ably through inhibition of cell migration into the CNS.
While it has been widely accepted that CNS inflammation
in MS patients is mediated mainly by the IFN-γ-secreting
Th1 cells, in recent years, Th17 cells have emerged as
major players in MS due to their high pathogenic potential
through the production of proinflammatory cytokine
IL-17A. In addition, as compared to Th1 cells, Th17
AB
C
Figure 8 Effect of MAb 5261-muIg on adoptively transferred
EAE in SJL/J mice. Mice were treated i.p. with 30 mg/kg of antibody
starting on the day of the adoptive transfer and twice a week thereafter
for the total of 4 weeks (n = 10 per group). (A) MAb 5261-muIg in
Th17-SJL EAE. (B) MAb 5261-muIg in Th17 vs. Th1 SJL-EAE: Th17 EAE:
GMS +/− SE (GMS calculated from three independent experiments);
Th1 EAE: GMS +/− SD (Results of one experiment +/− SD). (C) MAb
5261-muIg effect on muCXCL13-induced migration of Th17 and Th1 cells
from successful SJL/J passive EAE transfer experiments (concentrations:
5 μg/ml muCXCL13; 50 μg/ml of each antibody). Results are presented
as average of triplicate measurements +/− SE (except for Th1 cell
migration data which originated from a single measurement).
Statistical significance was evaluated using unpaired Student’s t-test
(A) and one-way ANOVA followed by Bonferroni’s multiple comparison
post test (B and C). **** P < 0.0001; *P < 0.1.
B
A
Figure 7 Effect of MAb 5261-muIg on relapsing-remitting EAE
in SJL/J mice. Mice (n = 15 per group) were treated starting on day 7
post-PLP139–151/CFA immunization with 30 mg/kg of MAb 5261-muIg
or an isotype control antibody i.p., once a week for 8 weeks. (A) Average
EAE scores during the course of the disease. (B) Group mean scores
(GMS). Statistical significance was evaluated using unpaired Student’s
t-test. *P < 0.1; ****P < 0.0001.
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of activation markers (e.g., CD5, CD69, human leukocyte
antigen-DR) and adhesion molecules (e.g., CD49d, CD6
and MCAM (CD146)) required for T cell penetration
into the brain, and reduced susceptibility to Treg-
induced suppression [59]. Clinically, in patients with
relapsing-remitting MS, the frequency of Th17 cells is
significantly elevated in cerebrospinal fluid (CSF) as
compared to blood; the frequency of Th17 cells in CSF
is significantly higher during relapse than in remission,
while the frequency of Th1 cells remains relatively
stable [59]. Moreover, in patients with aggressive MS
that were treated with ablative chemotherapy and au-
tologous hematopoietic stem cell transplantation, the
absence of new relapses and inflammatory brain lesions
2 years following treatment was linked to diminished
Th17 and Th1/17 cells (newly defined subset of Th cells
that express cytokines and transcription factors of both,
Th17 and Th1 lineages), but not Th1 responses, impli-
cating the former T-cell subsets’ involvement in MS
pathogenesis [60].
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able strategy for developing next-generation treatments
for MS. In fact, some of the approved MS therapies, in-
cluding Glatiramer Acetate [61,62], FTY720 [63] and
IFN-β [64], are capable of reducing Th17 responses in
both experimental autoimmune encephalomyelitis models
[61,62] and in patients with multiple sclerosis [63,64]. On
the other hand, ustekinumab, an IL-12/IL-23 monoclonal
antibody targeting Th17 differentiation, although well-
tolerated, failed to demonstrate efficacy in a Phase II clin-
ical study involving patients with relapsing-remitting MS
[65]. A monoclonal antibody targeting Th17 trafficking
into the CNS, such as the anti-CXCL13 antibody de-
scribed herein, may serve as a more effective strategy to
block Th17 cell-mediated pathologic effects and thereby
alleviate disease symptoms associated with MS.
As shown in Figure 4, MAb 5261-muIg significantly
inhibited B cell migration into spleens of naïve Balb/c
mice, while Kramer and colleagues recently demonstrated
that CXCL13 neutralization with MAb 5261-muIg in a
NOD mouse model of Sjogren’s syndrome caused re-
duction in salivary gland inflammation by inhibiting B
cell recruitment into submandibular gland tissue [38].
In an attempt to decipher the mechanism of action of
anti-CXCL13 antibody in animal models, Finch et al.
[66] examined the integrity of splenic architecture in
BALB/c mice immunized with alum-precipitated DNP-
OVA and treated with rat anti-mouse CXCL13 antibody
MAb 470 (R&D Systems, clone 143614). They found
that anti-CXCL13 treatment caused a disruption in
splenic follicular structure accompanied by a significant
reduction in germinal center frequency. The serum ti-
ters of DNP-OVA-specific IgG and the frequency of the
germinal center B cells were not affected by the treat-
ment. Similarly, MAb 5261-muIg caused a decline in
the number and size of splenic germinal centers of the
C57BL/6 mice immunized with alum-precipitated NP-
KLH (Figure 5C and D), but not a reduction in the fre-
quency of B220+/PNAhigh/CD38low GC B cells (data
not shown). While we have not assessed the serum titers
of NP-specific IgG, we did observe a significant decrease
in the frequency of NP-specific IgG1-secreting cells,
consistent with the effects reported by Arnold et al. [40]
in mice with CXCR5-deficient T cells.
Conclusions
In this report we describe the derivation and functional
testing of a novel human anti-human CXCL13 antibody,
MAb 5261, and provide its detailed pharmacological char-
acteristics. The antibody binds to human, mouse and cyno
CXCL13 with an affinity of approximately 5 nM. It effi-
ciently and specifically inhibits CXCL13-induced chemotaxis
of human and murine B cells as well as huCXCL13-
mediated CXCR5 receptor endocytosis. Importantly, theantibody is non-toxic as revealed by preclinical single-
dose rat PK study.
Its murine counterpart, MAb 5261-muIg, created spe-
cifically for in vivo preclinical studies, effectively inhibits B
and activated T-cell recruitment into secondary lymphoid
organs and germinal center formation in mice immunized
with thymus-dependent antigen and autoimmune mice.
Through its effect on the migration of immune cells,
MAb 5261-muIg inhibited progression and severity of
relapsing-remitting EAE and, specifically, Th17-induced
EAE in SJL mice and alleviated symptoms of arthritis in
mice immunized with Type II collagen.
Our results, therefore, indicate that CXCL13 neutral-
izing MAb 5261 antibody has potential for treatment of




Chemokines/Cytokines: recombinant human CXCL13
(Peprotech; 300–47); recombinant murine CXCL13
(Peprotech; 250–24); recombinant murine CXCL12
(Peprotech; 250-20A); recombinant human CXCL12
(Peprotech; 300-28A); recombinant murine IL-12
(R&D Systems; 419-ML/CF); recombinant murine IL-2
(R&D Systems; 402-ML); recombinant murine IL-6
(R&D Systems; 406-ML/CF); recombinant human TGF-β
(R&D Systems; 240-B); recombinant murine IL-23 (R&D
Systems; 1887-ML).
Antibodies: rat anti-mouse MAb 470 (R&D Systems;
MAB470); mouse anti-human MAb 801 (R&D Systems;
MAB801); goat anti-human AF801 (R&D Systems; AF801);
goat anti-mouse AF470 (R&D Systems; AF470); anti-
human CXCR5-Alexa 647 (BD Pharmingen; 558113); anti-
human CXCR4-APC (R&D Systems; FAB170A); donkey
anti-mouse IgG-HRP (Jackson ImmunoResearch; 715-035-
150); donkey anti-rat IgG-HRP (Jackson ImmunoResearch;
712-035-150); B220-FITC (BD Biosciences; 553087); CD21/
35-APC (BD Biosciences; 558658); CD23-PE (BD Biosci-
ences; 553139); anti-human CD32 (Biolegend; 303202);
anti-murine IL-4 (clone 11B11; BioXcell, BE0055); anti-
murine CD3e (clone 145-2C11; BioXcell; BE0001-1);
anti-murine CD28 (clone PV-1; BioXcell; BE0015-5);
anti-murine IFN-γ (clone XMG1.2; BioXcell; BE0055).
Reagents: PLP139–151 (Anaspec; 29213); MOG35–55
(Biosynthesis Inc.; 12668–01); NP-KLH (Biosearch Tech-
nologies; N-5060); Imject Alum (Thermo Fisher; PI-77161);
NP-BSA (Biosearch Technologies; N-5050); Imject BSA
(ThermoScientific; 77110); Imject KLH (ThermoScientific;
77600).
Generation of anti-human CXCL13 antibody, MAb 5261
We initially produced hybridomas secreting mouse anti-
human CXCL13 antibodies. Briefly, Swiss Webster mice
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After three immunizations, the spleen was harvested
from the mouse with the highest anti-CXCL13 titer and
hybridomas were generated by fusion of spleen cells with
SP2/0 myeloma cells using standard procedures. Hybrid-
oma cells were originally grown in DMEM supplemented
with 10% FBS, 4.5 g/ml glucose, L-glutamine and Na
pyruvate. The cells were subcloned by limiting dilution.
Twenty clones were expanded and gradually adjusted to
serum-free growing conditions in Excell 610-HSF hy-
bridoma serum-free medium. Hybridoma clones were
screened by ELISA for binding to human and murine
CXCL13. The antibody, called 3D2, that demonstrated
dual specificity on both murine and human CXCL13 be-
came a prototype for human anti-human CXCL13
generation.
The V genes were isolated from 3D2 hybridoma using
standard methods. The VH gene was cloned into a
mammalian expression vector that contained the human
gamma 1 heavy chain gene, creating a full-length chimeric
heavy chain. The VK was cloned into a mammalian ex-
pression vector that contained the human Kappa constant
gene, creating a full-length chimeric light chain. In order
to make the chimeric antibody, the expression vectors
harboring the chimeric heavy chain and the chimeric light
chain were co-transfected into CHO-S cells. The MAb
was secreted by the cells and harvested following a 3–6
day expression period. The resulting MAb was purified
using Protein A chromatography, and characterized. The
resulting chimeric IgG1 antibody was specific for human
and murine CXCL13 by ELISA, and demonstrated similar
affinity on murine and human CXCL13 and similar func-
tional activity as parental mouse antibody.
Generation of human anti-CXCL13 antibody through
humanization of chimeric antibody was accomplished as
follows. The following modifications were introduced to
FWR regions of heavy and light chains from the
chimeric antibody: (i) a putative N-linked glycosylation
site (NLT) in the heavy chain was replaced with “SLT”;
and (ii) a single serine to methionine mutation was in-
troduced at position 31 in light chain CDR1. The modi-
fications resulted in generation of human IgG1 antibody,
MAb 5261, which demonstrated significant improve-
ment in affinity as compared to the parental mouse anti-
CXCL13 antibody.
Generation of murine counterpart of MAb 5261 for use in
animal studies
MAb 5261 contains human heavy and light variable and
human IgGamma1-F allotype as well as human kappa.
Its murine counterpart, MAb 5261-muIg (a.k.a MAb
5378, [38]), had been engineered as a mouse IgG2a iso-
type. The murine antibody contains the same human
heavy and light chain variable genes as MAb 5261 alongwith mouse IgGamma2a constant region and mouse
kappa. Vaccinex has engineered common restriction
sites among all of our heavy and light chain expression
plasmids such that changing isotypes and species can
be achieved through restriction digestion, ligation, and
transformation. Specifically, for the MAb 5261 heavy
chain, the variable region of the gene was digested with
restriction endonucleases BssHII and BstEII and li-
gated into comparable sites in an expression plasmid
that contains the mouse IgGamma2a constant region
in order to make the heavy chain for MAb 5261-muIg.
Similarly, for the MAb 5261 light chain, the variable
region of the gene was digested with restriction endo-
nucleases ApaLI and XhoI and ligated into comparable
sites in an expression plasmid that contained the
mouse IgKappa constant region in order to make the
light chain for MAb 5261-muIg.
Screening hybridoma supernatants for anti-CXCL13
antibodies by ELISA
Supernatants were collected and screened for binding to
human and murine CXCL13 using the following protocol:
plates were coated with 1 μg/ml of human or murine
CXCL13 at room temperature overnight. After the plates
were washed and blocked, antibodies (MAb 470 and MAb
801 used as standard) at 1 μg/ml - 0.02 μg/ml serial dilu-
tions or hybridoma sups at 1:10–1:50,000 serial dilutions
were added and incubated at room temperature for one
hour. Plates were washed and secondary antibodies
(donkey anti-rat IgG- HRP for MAb 470; donkey anti-
mouse IgG-HRP for MAb 801 and hybridoma super-
natants) were added at 1:20,000 dilution. Plates were
incubated for 1 h at room temperature, washed, developed
for 15 min in the dark and read at 450/570 nm.
Affinity measurements by Biacore
Chemokines were immobilized on C1 chip in Acetate
buffer (pH = 5): human CXCL13 at 1 μg/ml, murine
CXCL13 at 0.3 μg/ml and negative control human
CXCL12 at 0.5 μg/ml. Monoclonal anti-CXCL13 anti-
bodies were diluted by 2-fold from 50 nM to 0.78 nM
for binding to human CXCL13 and from 19 nM to 0.594
nM for binding to murine CXCL13. The curves were an-
alyzed using Bivalent model.
Generation of human pre-B-697-huCXCR5 and huCXCR4
stable cell lines
Packaging cell lines were generated by transfecting
PA317 cells with LNCX2-hCXCR5 (or hCXCR4) retro-
viral constructs using “Fugene HD” transfection reagent
(Promega). Human pre-B-697 cells were infected with
retroviral sups collected of PA317-huCXCR5 or huCXCR4
cells using “spin infection” protocol: cells were centrifuged
with retroviral sups at 2500 rpm for three hours at room
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allowed to recover in drug-free culture medium for
twenty four hours. After that, the cells were placed
under selection with 0.4 mg/ml G418. Once resistant
cells reached ≥ 90% viability, they were flow sorted using
either anti-huCXCR5 or anti-huCXCR4 antibodies into
96-well plates. Clones were expanded and screened by
flow cytometry to select highest receptor expressors. Se-
lected clones were then tested in migration assays to de-
termine their functionality. If necessary, the clones were
subcloned by limiting dilution one more time.
Chemotaxis assay using human pre-B-697-huCXCR5 and
huCXCR4 cells
Transwell tissue culture treated plates with 8 μm pore
size and diameter of 6.5 mm (Corning Costar; 3422)
were used. Human pre-B-697-huCXCR5 cells were used
for huCXCL13-induced migration; human pre-B-697-
huCXCR4 cells for, negative control, huCXCL12-induced
migration. Cells were resuspended in chemotaxis medium
(RPMI 1640 with L-glutamine, 10 mM HEPES, Penicillin-
Streptomycin and 0.5% BSA) at 5×106/ml and re-
sensitized for thirty minutes at 37°C. Diluted chemokine
(1 μg/ml huCXCL13; 0.1 μg/ml huCXCL12 in chemo-
taxis buffer) +/− antibodies are added into the lower
chamber at 590 μl/well; pre-incubated for 15 min at
room temperature. The cells were added at 100 μl
(5×105 cells) per upper chamber. Plates were incubated
overnight at 37°C. Inserts were removed. Alamar blue
was added at 60 μl per well; plates were incubated at 37°C
for 4 h. Fluorescence was measured at wavelengths of
530 nm and 590 nm. Migration index and percent migra-
tion inhibition were calculated as follows:
%Migration index ¼ Specific migration ðChemokine
þMAb or Isotype ControlÞ
Spontaneous Migration
 No chemokine=No antibodyð Þ
%Migration inhibition ¼ ðMigration Index Chemokineð Þ
‐Migration Index Chemokine þ MAb0ð ÞÞ
100
Migration Index Chemokineð Þ
Chemotaxis assay using murine splenocytes and human
tonsil cells
Transwell tissue culture treated plates with 5 μm pore
size and diameter of 6.5 mm (Corning Costar; 3421)
were used. Mouse spleens and human tonsils were
crashed with 5-ml syringe plunger; passed through 40-
μm (spleens) or 70-μm (tonsils) filter. Red blood cells
were lysed with RBC lysis buffer (eBioscience) for 5 min
at room temperature. The cells were filtered and washed
twice with the chemotaxis medium. The cells wereresuspended at a density of 1×107 cells/ml in chemotaxis
medium and resensitized for 2–4 h at 37°C. Diluted che-
mokine (5 μg/ml of murine or human CXCL13 or
0.1 μg/ml of murine or human CXCL12) +/− antibodies
were added into the lower chamber at 590 μl/well and
pre-incubated for 15 min at room temperature. The cells
were added at 100 μl (106) cells per upper chamber.
Plates were incubated for 2 h at 37°C. Inserts were re-
moved. Alamar blue was added at 60 μl per well and in-
cubated at 37°C overnight. Fluorescence was measured
at wavelengths of 530 nm and 590 nm. Migration index
and migration inhibition were calculated as described
above.
Human CXCR5 receptor endocytosis assay
Working stocks of antibodies were serially diluted from
100 μg/ml to 4 μg/ml. Human CXCL13 was diluted to
20 μg/ml in cold diluent buffer (RPMI + 0.5% BSA).
Thirty microliters each of hCXCL13 and antibodies were
combined and incubated overnight at 4°C. The next day,
cells were resuspended in diluent buffer at 107 cells/ml.
Cells were pre-blocked with 10 μg/ml anti-human Fc
block for 15 min at 37°C. Cells were incubated with
huCXCL13/antibody mix (50 μl cells: 50 μl mix) for 2 h
at 37°C and stained with 15 μl anti-human CXCR5
antibody (30 min at 4°C). Inhibition of endocytosis was
calculated as follows: % Inhibition = 100 - [100*(0 CXCL13 -
geomean)/(0 CXCL13 - 0 mAB)]
Murine active immunization - induced experimental
autoimmune encephalomyelitis
Relapsing-remitting (RR) disease was induced in 8–10
week-old female SJL/J mice (Charles River Laboratories)
by subcutaneous immunization with PLP139–151 in 1 mg/ml
Complete Freund’s Adjuvant (CFA) enhanced with 5 mg
Mycobacterium tuberculosis strain H37RA (100 μl of PLP/
CFA emulsion were injected into four sites on the back of
the animal; 25 μl per site), using a pertussis toxin-free kit
from Hooke Laboratories, Inc (EK-0120). The treatment
started on day 7 post-immunization, lasted for 8 weeks
and consisted of weekly i.p. injections of 30 mg/kg of
anti-CXCL13 or control antibody. The clinical signs of
the disease were evaluated at least 5 times a week using
the following scoring system (adapted with modifica-
tions from Bagaeva et al. [47]: 0, normal behavior; 1, dis-
tal limp tail; 1.5, complete limp tail; 2, impaired righting
ability; 3, ataxia; 4, paralysis of one hind leg; 4.5, paraly-
sis of both hind legs; 5, full paralysis; and 6, death.
Murine passively induced experimental autoimmune
encephalomyelitis (adoptive transfer model)
The disease was induced in female 10–11 week-old SJL/J
(Charles River Laboratories) mice by adoptive transfer of
either Th1 or Th17 cells from immunized donors. First,
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nized with PLP139–151/CFA emulsion as described above.
On day 10 post-immunization, the animals were sacri-
ficed and T cells were isolated from spleens and lymph
nodes using the kit from Miltenyi Biotech (130-095-
248). For T helper subset differentiation, the cells were
plated with the irradiated APC (3400 rad) in media
(RPMI1640/10% FBS/Na Pyruvate/Non-essential amino
acids/2-mercaptoethanol/Penicillin-Streptomycin) con-
taining 20 μg/ml PLP139–151 and either 20 μg/ml anti-
muIL-4 and 10 ng/ml muIL-12 (Th1 cells) or 30 ng/ml
muIL-6, 3 ng/ml huTGF-β, 20 μg/ml anti-muIFN-γ and
20 μg/ml anti-muIL-4 (Th17 cells). The cells were incu-
bated at 37°C for 3 days. The cells were then mixed with
freshly irradiated APC and resuspended in media con-
taining 20 μg/ml PLP139–151 and either 20 U/ml muIL-2
(Th1 cells) or 10 ng/ml muIL-23 (Th17 cells). The cells
were incubated at 37°C for 4 days after which the cells
were collected, washed and cultured in media containing
2 μg/ml of each anti-muCD3e and anti-muCD28 anti-
body for 3 days. For the adoptive transfer, the mice were
injected i.p. with 2×106 cells in 100 μl PBS. Starting on
the day of the adoptive transfer, the animals were given
bi-weekly i.p. injections of 30 mg/kg of the antibodies
for the total of 4 weeks.
Adoptive transfer of B cells
B cells were isolated from untreated 8–12 week-old fe-
male BALB/c donor mice (Taconic Farms) using a kit
(Miltenyi Biotech (130-090-862)). Donor B cells were la-
beled with 1 μM CFSE (Molecular Probes; C34554) and
injected (2X107 cells/i.v.) into syngeneic recipients pre-
treated with i.p. injections of 30 mg/kg of either isotype
control antibody or anti-CXCL13 antibody for 2 weeks
pre-transfer. Twenty four hours post-transfer, recipients
were sacrificed, spleens collected and analyzed by flow
cytometry and IHC.
Germinal center study
Male 8–10 week-old C57BL/6 mice (Jackson Laboratories)
were immunized i.p. with 100 μg NP-KLH precipitated in
100 μl Imject Alum in 100 μl PBS. The animals were
treated with i.p. injections of 30 mg/kg of anti-CXCL13
antibody or corresponding isotype control antibody on
days −3, 0, 4 and 7 relative to the immunization day. The
animals were euthanized on day 12 post-immunization.
Spleens and bone marrow were collected from all animals.
The spleens were bisected longitudinally for separate
IHC and ELISPOT analyses. Bone marrow was used for
FACS analysis.
Animal studies described above were conducted at the
AAALAC (Association for Assessment and Accreditation
of Laboratory Animal Care International) accredited ani-
mal husbandry facilities at the University of Rochester,institution compliant with the Public Health Service Policy
on Humane Care and Use of Laboratory Animals (U.S.
Department of Agriculture (USDA) registration number
21-R-019; Animal welfare Assurance Statement A-3292-
01). Experimental protocols were approved by the Univer-
sity Committee on Animal Resources (UCAR).
Murine collagen-induced arthritis
Studies were conducted at Washington Biotechnology,
Inc., in vivo services Contract Research Organization
(CRO) for drug development. The animals were main-
tained and treated in the facilities accredited by AAA-
LAC in compliance with NIH and USDA standards
(USDA registration number 51-R-031; Animal Welfare
Assurance Statement A- 4192–01).
Male, 5–6 weeks old, DBA1/J mice (Jackson Labora-
tories) were immunized with 100 μg of bovine Type II
collagen in CFA enhanced with 100 μg of heat-killed
Mycobacterium tuberculosis strain H37RA (50 μl of
collagen/CFA emulsion were injected subcutaneously
at the base of the tail). Prophylactic treatment started
on day 20 post initial immunization. On day 21 the
mice were given a booster subcutaneous injection of
bovine Type II collagen in Incomplete Freund Adjuvant
(IFA). Therapeutic treatment started on day 30 post-initial
immunization. The animals had been scored for macro-
scopic signs of arthritis 3 times weekly using a stan-
dardized scoring system (provided by Washington
Biotechnology, Inc): 0, no visible signs of arthritis; 1,
edema and/or erythema of 1 digit; 2, edema and/or ery-
thema of 2 digits; 3, edema and/or erythema of more
than 2 digits; and 4, severe arthritis of entire paw and
digits. Arthritic Index (AI) was calculated by addition
of individual paw scores. The maximum arthritic index
that could be achieved in any given animal was 16.
For histological evaluation, all four limbs were re-
moved and individually preserved in 20 volumes of 10%
neutral buffered formalin. After decalcification in 5%
formic acid for 2–3 days, tissues were trimmed, proc-
essed for paraffin embedding, sectioned at 8 μm and
stained with toluidine blue. Paws were embedded and
sectioned in the frontal plane. When scoring paws or an-
kles from mice with lesions of type II collagen arthritis,
severity of changes as well as number of individual joints
affected were considered. When only 1–3 joints of the
paws or ankles out of a possibility of numerous metacar-
pal/metatarsal/digit or tarsal/tibiotarsal joints were af-
fected, an arbitrary assignment of a maximum score of
1, 2 or 3 for parameters below was given depending on
severity of changes. If more than 3 joints were involved,
the criteria below were applied to the most severely af-
fected/majority of joints. The following parameters were
taken into account when scoring the joints for severity
of arthritis: inflammation, pannus formation, cartilage
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was used: 0, Normal; 1, Minimal changes; 2, Mild changes;
3, Moderate changes; 4, Marked changes; 5, Severe
changes.
ELISPOT
The membranes of the Millipore plates (Millipore;
MSIPS4510) were activated with 35% ETOH prior to
coating. The membranes were coated with 10 μg/ml of
each of the following reagents diluted in DPBS: NP4-
BSA; NP14-BSA, Imject BSA, Imject KLH. The plates
were incubated at 4°C overnight. Plates were washed
and blocked with 10% goat serum (Gibco) diluted in
tissue culture medium (RPMI 1640/Penicillin-Streptomycin/
L-Glutamine and 5x10−5 M 2-mercaptoethanol) for 2 h at
room temperature. Mouse splenocytes were resuspended
in tissue culture medium supplemented with 10% FBS,
added at 2×106 cells per well and cultured for 48 h at
37°C. The plates were developed using AEC substrate
solution (BD; 551951) and sent for analysis to Cellular
Technology, LTD.
Statistical analysis
Statistical analysis was performed using Graphpad Prizm
5 software.
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